Skip to main content
Erschienen in: Heart and Vessels 5/2014

01.09.2014 | Original Article

Plasma urokinase antigen and C-reactive protein predict angina recurrence after coronary angioplasty

verfasst von: Yelena Parfyonova, Irina Alekseeva, Olga Plekhanova, Alexander Deev, Elena Titaeva, Anatoly Dobrovolsky, Zufar Gabbasov, Anatoly Lyakishev, Vsevolod Tkachuk

Erschienen in: Heart and Vessels | Ausgabe 5/2014

Einloggen, um Zugang zu erhalten

Abstract

This study evaluates the predictive value of several biochemical indices of the coagulation–fibrinolysis system, platelet function, and inflammatory state for angina recurrence after successful percutaneous transluminal coronary angioplasty (PTCA). We measured preprocedural and follow-up plasma levels of C-reactive protein (CRP), fibrinogen, and urokinase plasminogen activator antigen (uPA), plasminogen activator inhibitor-1 (PAI-1) activity, tissue plasminogen activator activity, and adenosine diphosphate-induced platelet aggregation in 53 patients with chronic stable angina who underwent successful elective PTCA of single hemodynamically significant lesions in coronary arteries. All patients were followed up for 12 months after PTCA. The Cox proportional hazards model was used to assess the association of variables with angina recurrence rate. At the end of the follow-up, 16 patients had angina recurrence. Among 36 clinical, biochemical, and angiographic variables, the duration of stable angina more than 12 months before PTCA (χ 2 = 5.73; P = 0.02, hazard ratio (HR) 3.7, 95 % confidence interval (CI) 1.26–10.6), high baseline levels of CRP (>7 mg/l) (χ 2 = 8.34; P = 0.004, HR 2.9, 95 % CI 1.4–5.9), uPA antigen baseline (>1 ng/ml) (χ 2 = 17.11; P = 0.0001, HR 11.5, 95 % CI 3.6–36.7) and 48 h after PTCA (χ 2 = 15.73; P = 0.0001, HR 8.8, 95 % CI 3.01–25.96), baseline PAI-1 activity (>18 IU/ml) (χ 2 = 9.37; P = 0.002, HR 7.6, 95 % CI 2.07–27.84) were significant predictors of recurrent angina by univariate analyses. According to stepwise multivariate analyses, only the levels of plasma uPA antigen and serum CRP were shown to be significant independent predictors of angina recurrence (multivariate uPA χ 2 = 8.22, P = 0.004, HR 6.2, 95 % CI 1.78–21.67; CRP χ 2 = 4.09, P = 0.04, HR 1.9, 95 % CI 1.02–3.68). High preprocedural plasma uPA and serum CRP levels are indicative of angina recurrence after successful PTCA, and are valuable for the prognosis of restenosis.
Literatur
1.
Zurück zum Zitat Bhoday J, de Silva S, Xu Q (2006) The molecular mechanisms of vascular restenosis: which genes are crucial? Curr Vasc Pharmacol 4:269–275PubMedCrossRef Bhoday J, de Silva S, Xu Q (2006) The molecular mechanisms of vascular restenosis: which genes are crucial? Curr Vasc Pharmacol 4:269–275PubMedCrossRef
2.
Zurück zum Zitat Klomp M, Damman P, Beijk MA, Silber S, Grisold M, Ribeiro EE, Suryapranata H, Wòjcik J, Sim KH, Tijssen JG, de Winter RJ, e-HEALING investigators, (2012) Applying the National Institute for Clinical Excellence criteria to patients treated with the Genous™ Bio-engineered R stent™: a sub-study of the e-HEALING (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth) worldwide registry. Heart Vessels 27(4):360–369PubMedCrossRef Klomp M, Damman P, Beijk MA, Silber S, Grisold M, Ribeiro EE, Suryapranata H, Wòjcik J, Sim KH, Tijssen JG, de Winter RJ, e-HEALING investigators, (2012) Applying the National Institute for Clinical Excellence criteria to patients treated with the Genous™ Bio-engineered R stent™: a sub-study of the e-HEALING (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth) worldwide registry. Heart Vessels 27(4):360–369PubMedCrossRef
3.
Zurück zum Zitat Biasucci LM (2004) CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: application to Clinical and Public Health Practice: clinical use of inflammatory markers in patients with cardiovascular diseases: a background paper. Circulation 110:e560–e567PubMedCrossRef Biasucci LM (2004) CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: application to Clinical and Public Health Practice: clinical use of inflammatory markers in patients with cardiovascular diseases: a background paper. Circulation 110:e560–e567PubMedCrossRef
4.
Zurück zum Zitat Strauss BH, Lau HK, Bowman KA, Sparkes J, Chisholm RJ, Garvey MB, Fenkell LL, Natarajan MK, Singh I, Teitel JM (1999) Plasma urokinase antigen and plasminogen activator inhibitor-1 antigen levels predict angiographic coronary restenosis. Circulation 100:1616–1622PubMedCrossRef Strauss BH, Lau HK, Bowman KA, Sparkes J, Chisholm RJ, Garvey MB, Fenkell LL, Natarajan MK, Singh I, Teitel JM (1999) Plasma urokinase antigen and plasminogen activator inhibitor-1 antigen levels predict angiographic coronary restenosis. Circulation 100:1616–1622PubMedCrossRef
5.
Zurück zum Zitat Gurbel PA, Bliden KP, Guyer K, Cho PW, Zaman KA, Kreutz RP, Bassi AK, Tantry US (2005) Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 46:1820–1826PubMedCrossRef Gurbel PA, Bliden KP, Guyer K, Cho PW, Zaman KA, Kreutz RP, Bassi AK, Tantry US (2005) Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 46:1820–1826PubMedCrossRef
6.
Zurück zum Zitat Ikeda U, Hojo Y, Shimada K (2000) Plasma urokinase antigen and plasminogen activator inhibitor-1 antigen levels predict angiographic coronary restenosis. Circulation 102:E167PubMedCrossRef Ikeda U, Hojo Y, Shimada K (2000) Plasma urokinase antigen and plasminogen activator inhibitor-1 antigen levels predict angiographic coronary restenosis. Circulation 102:E167PubMedCrossRef
7.
Zurück zum Zitat Krasnikova TL, Parfyonova Y, Alekseeva IA, Arefieva TI, Mukhina SA, Dobrovolsky AB, Titaeva Y, Lyakishev AA, Resink TJ, Erne P, Tkachuk VA (1999) Urokinase plasminogen activator system in humans with stable coronary artery disease. Clin Exp Pharmacol Physiol 26:354–357PubMedCrossRef Krasnikova TL, Parfyonova Y, Alekseeva IA, Arefieva TI, Mukhina SA, Dobrovolsky AB, Titaeva Y, Lyakishev AA, Resink TJ, Erne P, Tkachuk VA (1999) Urokinase plasminogen activator system in humans with stable coronary artery disease. Clin Exp Pharmacol Physiol 26:354–357PubMedCrossRef
8.
Zurück zum Zitat Gabbasov Z, Parfyonova Y, Popov E, Gavrilov I, Anuchin V, Dubov P, Djakonova Y (1998) Association of platelet function in hypertensive patients with left ventricular hypertrophy, transient myocardial ischemia, and coronary artery disease. Platelets 9:191–195PubMedCrossRef Gabbasov Z, Parfyonova Y, Popov E, Gavrilov I, Anuchin V, Dubov P, Djakonova Y (1998) Association of platelet function in hypertensive patients with left ventricular hypertrophy, transient myocardial ischemia, and coronary artery disease. Platelets 9:191–195PubMedCrossRef
9.
Zurück zum Zitat Tkachuk VA, Plekhanova OS, Parfyonova YV (2009) Regulation of arterial remodeling and angiogenesis by urokinase-type plasminogen activator. Can J Physiol Pharmacol 87:231–251PubMedCrossRef Tkachuk VA, Plekhanova OS, Parfyonova YV (2009) Regulation of arterial remodeling and angiogenesis by urokinase-type plasminogen activator. Can J Physiol Pharmacol 87:231–251PubMedCrossRef
10.
Zurück zum Zitat Christ G, Kostner K, Zehetgruber M, Binder BR, Gulba D, Huber K (1999) Plasmin activation system in restenosis: role in pathogenesis and clinical prediction? J Thromb Thrombolysis 7:277–285PubMedCrossRef Christ G, Kostner K, Zehetgruber M, Binder BR, Gulba D, Huber K (1999) Plasmin activation system in restenosis: role in pathogenesis and clinical prediction? J Thromb Thrombolysis 7:277–285PubMedCrossRef
11.
Zurück zum Zitat Fornitz GG, Nielsen P, Amtorp O, Kassis E, Abildgard U, Sloth C, Winther K, Orskov H, Dalsgard J, Husted S (2001) Impaired fibrinolysis determines the outcome of percutaneous transluminal coronary angioplasty (PTCA). Eur J Clin Invest 31:586–592PubMedCrossRef Fornitz GG, Nielsen P, Amtorp O, Kassis E, Abildgard U, Sloth C, Winther K, Orskov H, Dalsgard J, Husted S (2001) Impaired fibrinolysis determines the outcome of percutaneous transluminal coronary angioplasty (PTCA). Eur J Clin Invest 31:586–592PubMedCrossRef
12.
Zurück zum Zitat Sakata K, Miura F, Sugino H, Shinobe M, Shirotani M, Yoshida H, Mori N, Hoshino T, Takada A (1996) Impaired fibrinolysis early after percutaneous transluminal coronary angioplasty is associated with restenosis. Am Heart J 131:1–6PubMedCrossRef Sakata K, Miura F, Sugino H, Shinobe M, Shirotani M, Yoshida H, Mori N, Hoshino T, Takada A (1996) Impaired fibrinolysis early after percutaneous transluminal coronary angioplasty is associated with restenosis. Am Heart J 131:1–6PubMedCrossRef
13.
Zurück zum Zitat Garg N, Fay WP (2007) Plasminogen activator inhibitor-1 and restenosis. Curr Drug Targets 8:1003–1006PubMedCrossRef Garg N, Fay WP (2007) Plasminogen activator inhibitor-1 and restenosis. Curr Drug Targets 8:1003–1006PubMedCrossRef
14.
Zurück zum Zitat Katsaros KM, Speidl WS, Kastl SP, Zorn G, Huber K, Maurer G, Glogar D, Wojta J, Christ G (2008) Plasminogen activator inhibitor-1 predicts coronary in-stent restenosis of drug-eluting stents. J Thromb Haemost 6:508–513PubMedCrossRef Katsaros KM, Speidl WS, Kastl SP, Zorn G, Huber K, Maurer G, Glogar D, Wojta J, Christ G (2008) Plasminogen activator inhibitor-1 predicts coronary in-stent restenosis of drug-eluting stents. J Thromb Haemost 6:508–513PubMedCrossRef
15.
Zurück zum Zitat Prisco D, Fedi S, Antonucci E, Capanni M, Chiarugi L, Chioccioli M, Falai M, Giglioli C, Abbate R, Gensini GF (2001) Postprocedural PAI-1 activity is a risk marker of subsequent clinical restenosis in patients both with and without stent implantation after elective balloon PTCA. Thromb Res 104:181–186PubMedCrossRef Prisco D, Fedi S, Antonucci E, Capanni M, Chiarugi L, Chioccioli M, Falai M, Giglioli C, Abbate R, Gensini GF (2001) Postprocedural PAI-1 activity is a risk marker of subsequent clinical restenosis in patients both with and without stent implantation after elective balloon PTCA. Thromb Res 104:181–186PubMedCrossRef
16.
Zurück zum Zitat Alaigh P, Hoffman CJ, Korlipara G, Neuroth A, Dervan JP, Lawson WE, Hultin MB (1998) Lipoprotein(a) level does not predict restenosis after percutaneous transluminal coronary angioplasty. Arterioscler Thromb Vasc Biol 18:1281–1286PubMedCrossRef Alaigh P, Hoffman CJ, Korlipara G, Neuroth A, Dervan JP, Lawson WE, Hultin MB (1998) Lipoprotein(a) level does not predict restenosis after percutaneous transluminal coronary angioplasty. Arterioscler Thromb Vasc Biol 18:1281–1286PubMedCrossRef
17.
Zurück zum Zitat Raghunath PN, Tomaszewski JE, Brady ST, Caron RJ, Okada SS, Barnathan ES (1995) Plasminogen activator system in human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 15:1432–1443PubMedCrossRef Raghunath PN, Tomaszewski JE, Brady ST, Caron RJ, Okada SS, Barnathan ES (1995) Plasminogen activator system in human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 15:1432–1443PubMedCrossRef
18.
Zurück zum Zitat Plekhanova O, Parfyonova Y, Bibilashvily R, Domogatskii S, Stepanova V, Gulba DC, Agrotis A, Bobik A, Tkachuk V (2001) Urokinase plasminogen activator augments cell proliferation and neointima formation in injured arteries via proteolytic mechanisms. Atherosclerosis 159:297–306PubMedCrossRef Plekhanova O, Parfyonova Y, Bibilashvily R, Domogatskii S, Stepanova V, Gulba DC, Agrotis A, Bobik A, Tkachuk V (2001) Urokinase plasminogen activator augments cell proliferation and neointima formation in injured arteries via proteolytic mechanisms. Atherosclerosis 159:297–306PubMedCrossRef
19.
Zurück zum Zitat Carmeliet P, Moons L, Herbert JM, Crawley J, Lupu F, Lijnen R, Collen D (1997) Urokinase but not tissue plasminogen activator mediates arterial neointima formation in mice. Circ Res 81:829–839PubMedCrossRef Carmeliet P, Moons L, Herbert JM, Crawley J, Lupu F, Lijnen R, Collen D (1997) Urokinase but not tissue plasminogen activator mediates arterial neointima formation in mice. Circ Res 81:829–839PubMedCrossRef
20.
Zurück zum Zitat Plekhanova OS, Parfyonova YV, Bibilashvily RS, Stepanova VV, Erne P, Bobik A, Tkachuk VA (2000) Urokinase plasminogen activator enhances neointima growth and reduces lumen size in injured carotid arteries. J Hypertens 18:1065–1069PubMedCrossRef Plekhanova OS, Parfyonova YV, Bibilashvily RS, Stepanova VV, Erne P, Bobik A, Tkachuk VA (2000) Urokinase plasminogen activator enhances neointima growth and reduces lumen size in injured carotid arteries. J Hypertens 18:1065–1069PubMedCrossRef
21.
Zurück zum Zitat Plekhanova O, Berk BC, Bashtrykov P, Brooks AI, Tkachuk V, Parfyonova Y (2009) Oligonucleotide microarrays reveal regulated genes related to inward arterial remodeling induced by urokinase plasminogen activator. J Vasc Res 46:177–187PubMedCrossRef Plekhanova O, Berk BC, Bashtrykov P, Brooks AI, Tkachuk V, Parfyonova Y (2009) Oligonucleotide microarrays reveal regulated genes related to inward arterial remodeling induced by urokinase plasminogen activator. J Vasc Res 46:177–187PubMedCrossRef
22.
Zurück zum Zitat Parfyonova Y, Plekhanova O, Solomatina M, Naumov V, Bobik A, Berk B, Tkachuk V (2004) Contrasting effects of urokinase and tissue-type plasminogen activators on neointima formation and vessel remodelling after arterial injury. J Vasc Res 41:268–276PubMedCrossRef Parfyonova Y, Plekhanova O, Solomatina M, Naumov V, Bobik A, Berk B, Tkachuk V (2004) Contrasting effects of urokinase and tissue-type plasminogen activators on neointima formation and vessel remodelling after arterial injury. J Vasc Res 41:268–276PubMedCrossRef
24.
Zurück zum Zitat Degoma EM, Dunbar RL, Jacoby D, French B (2013) Differences in absolute risk of cardiovascular events using risk-refinement tests: a systematic analysis of four cardiovascular risk equations. Atherosclerosis 227:172–177PubMedCrossRef Degoma EM, Dunbar RL, Jacoby D, French B (2013) Differences in absolute risk of cardiovascular events using risk-refinement tests: a systematic analysis of four cardiovascular risk equations. Atherosclerosis 227:172–177PubMedCrossRef
25.
Zurück zum Zitat Hoshida S, Nishino M, Takeda T, Tanouchi J, Yamada Y, Hori M (2004) A persistent increase in C-reactive protein is a risk factor for restenosis in patients with stable angina who are not receiving statins. Atherosclerosis 173:285–290PubMedCrossRef Hoshida S, Nishino M, Takeda T, Tanouchi J, Yamada Y, Hori M (2004) A persistent increase in C-reactive protein is a risk factor for restenosis in patients with stable angina who are not receiving statins. Atherosclerosis 173:285–290PubMedCrossRef
26.
Zurück zum Zitat Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB (1997) Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 349:462–466PubMedCrossRef Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB (1997) Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 349:462–466PubMedCrossRef
27.
Zurück zum Zitat Heinrich J, Schulte H, Schonfeld R, Kohler E, Assmann G (1995) Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain. Thromb Haemost 73:374–379PubMed Heinrich J, Schulte H, Schonfeld R, Kohler E, Assmann G (1995) Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain. Thromb Haemost 73:374–379PubMed
28.
Zurück zum Zitat Laframboise WA, Dhir R, Kelly LA, Petrosko P, Krill-Burger JM, Sciulli CM, Lyons-Weiler MA, Chandran UR, Lomakin A, Masterson RV, Marroquin OC, Mulukutla SR, McNamara DM (2012) Serum protein profiles predict coronary artery disease in symptomatic patients referred for coronary angiography. BMC Med 10:157PubMedCrossRefPubMedCentral Laframboise WA, Dhir R, Kelly LA, Petrosko P, Krill-Burger JM, Sciulli CM, Lyons-Weiler MA, Chandran UR, Lomakin A, Masterson RV, Marroquin OC, Mulukutla SR, McNamara DM (2012) Serum protein profiles predict coronary artery disease in symptomatic patients referred for coronary angiography. BMC Med 10:157PubMedCrossRefPubMedCentral
29.
Zurück zum Zitat Xu HY, Qiao SB, Zhang JF, Dong QT, Li JJ (2012) Different impacts of C-reactive protein and lipid profile on coronary lesions following a percutaneous coronary intervention. Coron Artery Dis 23:181–187PubMedCrossRef Xu HY, Qiao SB, Zhang JF, Dong QT, Li JJ (2012) Different impacts of C-reactive protein and lipid profile on coronary lesions following a percutaneous coronary intervention. Coron Artery Dis 23:181–187PubMedCrossRef
30.
Zurück zum Zitat Kardys I, Oemrawsingh RM, Kay IP, Jones GT, McCormick SP, Daemen J, Van Geuns RJ, Boersma E, Van Domburg RT, Serruys PW (2012) Lipoprotein(a), interleukin-10, C-reactive protein, and 8-year outcome after percutaneous coronary intervention. Clin Cardiol 35:482–489PubMedCrossRef Kardys I, Oemrawsingh RM, Kay IP, Jones GT, McCormick SP, Daemen J, Van Geuns RJ, Boersma E, Van Domburg RT, Serruys PW (2012) Lipoprotein(a), interleukin-10, C-reactive protein, and 8-year outcome after percutaneous coronary intervention. Clin Cardiol 35:482–489PubMedCrossRef
31.
Zurück zum Zitat Yano H, Horinaka S, Yagi H, Ishimitsu T (2013) Comparison of inflammatory response after implantation of sirolimus- and paclitaxel-eluting stents in patients on hemodialysis. Heart Vessels 28(3):308–315PubMedCrossRef Yano H, Horinaka S, Yagi H, Ishimitsu T (2013) Comparison of inflammatory response after implantation of sirolimus- and paclitaxel-eluting stents in patients on hemodialysis. Heart Vessels 28(3):308–315PubMedCrossRef
32.
Zurück zum Zitat Grad E, Danenberg HD (2013) C-reactive protein and atherothrombosis: cause or effect? Blood Rev 27:23–29PubMedCrossRef Grad E, Danenberg HD (2013) C-reactive protein and atherothrombosis: cause or effect? Blood Rev 27:23–29PubMedCrossRef
33.
Zurück zum Zitat Park DW, Yun SC, Lee JY, Kim WJ, Kang SJ, Lee SW, Kim YH, Lee CW, Kim JJ, Park SW, Park SJ (2009) C-reactive protein and the risk of stent thrombosis and cardiovascular events after drug-eluting stent implantation. Circulation 120(20):1987–1995PubMedCrossRef Park DW, Yun SC, Lee JY, Kim WJ, Kang SJ, Lee SW, Kim YH, Lee CW, Kim JJ, Park SW, Park SJ (2009) C-reactive protein and the risk of stent thrombosis and cardiovascular events after drug-eluting stent implantation. Circulation 120(20):1987–1995PubMedCrossRef
34.
Zurück zum Zitat Schoos MM, Kelbæk H, Kofoed KF, Køber L, Kløvgaard L, Helqvist S, Engstrøm T, Saunamäki K, Jørgensen E, Holmvang L, Clemmensen P (2011) Usefulness of preprocedure high-sensitivity C-reactive protein to predict death, recurrent myocardial infarction, and stent thrombosis according to stent type in patients with ST-segment elevation myocardial infarction randomized to bare metal or drug-eluting stenting during primary percutaneous coronary intervention. Am J Cardiol 107(11):1597–1603PubMedCrossRef Schoos MM, Kelbæk H, Kofoed KF, Køber L, Kløvgaard L, Helqvist S, Engstrøm T, Saunamäki K, Jørgensen E, Holmvang L, Clemmensen P (2011) Usefulness of preprocedure high-sensitivity C-reactive protein to predict death, recurrent myocardial infarction, and stent thrombosis according to stent type in patients with ST-segment elevation myocardial infarction randomized to bare metal or drug-eluting stenting during primary percutaneous coronary intervention. Am J Cardiol 107(11):1597–1603PubMedCrossRef
35.
Zurück zum Zitat Jeong HC, Ahn Y, Hong YJ, Kim JH, Jeong MH, Kim YJ, Chae SC, Cho MC; Other KAMIR (Korea Acute Myocardial Infarction Registry) Investigators (2012) Statin therapy to reduce stent thrombosis in acute myocardial infarction patients with elevated high-sensitivity C-reactive protein. Int J Cardiol. doi:10.1016/j.ijcard.2012.04.123 Jeong HC, Ahn Y, Hong YJ, Kim JH, Jeong MH, Kim YJ, Chae SC, Cho MC; Other KAMIR (Korea Acute Myocardial Infarction Registry) Investigators (2012) Statin therapy to reduce stent thrombosis in acute myocardial infarction patients with elevated high-sensitivity C-reactive protein. Int J Cardiol. doi:10.​1016/​j.​ijcard.​2012.​04.​123
36.
Zurück zum Zitat Tschopl M, Tsakiris DA, Marbet GA, Labs KH, Jager K (1997) Role of hemostatic risk factors for restenosis in peripheral arterial occlusive disease after transluminal angioplasty. Arterioscler Thromb Vasc Biol 17:3208–3214PubMedCrossRef Tschopl M, Tsakiris DA, Marbet GA, Labs KH, Jager K (1997) Role of hemostatic risk factors for restenosis in peripheral arterial occlusive disease after transluminal angioplasty. Arterioscler Thromb Vasc Biol 17:3208–3214PubMedCrossRef
37.
Zurück zum Zitat Benchimol D, Dubroca B, Dufourq P, Benchimol H, Couffinhal T, Dartigues JF, Bonnet J (1997) Restenosis or rapid progression in non-dilated sites are not predictors of late spontaneous coronary events. Int J Cardiol 60:201–211PubMedCrossRef Benchimol D, Dubroca B, Dufourq P, Benchimol H, Couffinhal T, Dartigues JF, Bonnet J (1997) Restenosis or rapid progression in non-dilated sites are not predictors of late spontaneous coronary events. Int J Cardiol 60:201–211PubMedCrossRef
38.
Zurück zum Zitat Price JF, Mamode N, Smith FB, Woodburn KR, Rumley A, Lowe GD, Fowkes FG (1997) Haemostatic and rheological factors as predictors of restenosis following percutaneous transluminal angioplasty. Eur J Vasc Endovasc Surg 14:392–398PubMedCrossRef Price JF, Mamode N, Smith FB, Woodburn KR, Rumley A, Lowe GD, Fowkes FG (1997) Haemostatic and rheological factors as predictors of restenosis following percutaneous transluminal angioplasty. Eur J Vasc Endovasc Surg 14:392–398PubMedCrossRef
39.
Zurück zum Zitat Le BH, Plow EF, Topol EJ (1996) Role of platelets in restenosis after percutaneous coronary revascularization. J Am Coll Cardiol 28:1643–1651CrossRef Le BH, Plow EF, Topol EJ (1996) Role of platelets in restenosis after percutaneous coronary revascularization. J Am Coll Cardiol 28:1643–1651CrossRef
40.
Zurück zum Zitat Ishiwata S, Tukada T, Nakanishi S, Nishiyama S, Seki A (1997) Postangioplasty restenosis: platelet activation and the coagulation–fibrinolysis system as possible factors in the pathogenesis of restenosis. Am Heart J 133:387–392PubMedCrossRef Ishiwata S, Tukada T, Nakanishi S, Nishiyama S, Seki A (1997) Postangioplasty restenosis: platelet activation and the coagulation–fibrinolysis system as possible factors in the pathogenesis of restenosis. Am Heart J 133:387–392PubMedCrossRef
Metadaten
Titel
Plasma urokinase antigen and C-reactive protein predict angina recurrence after coronary angioplasty
verfasst von
Yelena Parfyonova
Irina Alekseeva
Olga Plekhanova
Alexander Deev
Elena Titaeva
Anatoly Dobrovolsky
Zufar Gabbasov
Anatoly Lyakishev
Vsevolod Tkachuk
Publikationsdatum
01.09.2014
Verlag
Springer Japan
Erschienen in
Heart and Vessels / Ausgabe 5/2014
Print ISSN: 0910-8327
Elektronische ISSN: 1615-2573
DOI
https://doi.org/10.1007/s00380-013-0407-1

Weitere Artikel der Ausgabe 5/2014

Heart and Vessels 5/2014 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.